Ferriprox Twice-a-day

Ferriprox Twice-a-day Uses, Dosage, Side Effects, Food Interaction and all others data.

Ferriprox Twice-a-day is a chelating agent with an affinity for ferric ion (iron III). Ferriprox Twice-a-day binds with ferric ions to form neutral 3:1 (deferiprone:iron) complexes that are stable over a wide range of pH values. Ferriprox Twice-a-day has a lower binding affinity for other metals such as copper, aluminum and zinc than for iron.

Trade Name Ferriprox Twice-a-day
Availability Prescription only
Generic Deferiprone
Deferiprone Other Names Deferiprona, Défériprone, Deferiprone, Deferipronum
Related Drugs deferasirox, Jadenu, Exjade, Ferriprox
Weight 100mg/ml, 1000mg, 500mg
Type Oral liquid, oral tablet
Formula C7H9NO2
Weight Average: 139.1519
Monoisotopic: 139.063328537
Protein binding

Plasma protein binding is less than 10%.

Groups Approved
Therapeutic Class Antidote preparations
Available Country United States
Last Updated: September 19, 2023 at 7:00 am
Ferriprox Twice-a-day
Ferriprox Twice-a-day


Iron overload in patients with thalassaemia.

Ferriprox Twice-a-day is also used to associated treatment for these conditions: Transfusional Iron Overload

How Ferriprox Twice-a-day works

Ferriprox Twice-a-day is an iron chelator that binds to ferric ions (iron III) and forms a 3:1 (deferiprone:iron) stable complex and is then eliminated in the urine. Ferriprox Twice-a-day is more selective for iron in which other metals such as zinc, copper, and aluminum have a lower affinity for deferiprone.


Ferriprox Twice-a-day dosage

Adult: 25 mg/kg tid. Doses >100 mg/kg daily are not recommended.

Child: >6 yr: 25 mg/kg tid.

May be taken with or without food.

Side Effects

Musculoskeletal and joint pain; GI disturbances; red-brown discoloration of urine; transient liver enzyme abnormalities; zinc deficiency; neutropenia and agranulocytosis.


Agranulocytosis and neutropenia may occur, which can lead to fatal infections. Hepatoxicity is also possible. Most common side effects that lead to discontinuation of therapy were the gastrointestinal adverse effects (diarrhea, ulcer, nausea, gastrointestinal disturbances)


Hepatic and renal impairment. Neutropenia, monitor neutrophil count wkly and discontinue treatment if neutropenia develops. Limited experience in children 6-10 yr.


Avoid using deferiprone with aluminium-containing antacids as it can chelates trivalent metal ions.

Food Interaction

  • Take with or without food. Food does not affect absorption.

Ferriprox Twice-a-day multivitamins interaction

[Moderate] ADJUST DOSING INTERVAL: Ferriprox Twice-a-day has the potential to bind polyvalent cations such as aluminum, iron and zinc, which may reduce its effectiveness.

However, concurrent use with foods, mineral supplements, or antacids that contain polyvalent cations has not been studied.

A minimum 4-hour interval is recommended between the administration of deferiprone and mineral supplements or oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution) or other polyvalent cations.

Ferriprox Twice-a-day Disease Interaction

Major: agranulocytosis/neutropeniaModerate: hepatic impairment

Volume of Distribution

In healthy patients, the volume of distribution is 1L/kg, and in thalassemia patients, the volume of distribution is 1.6L/kg.

Elimination Route

Ferriprox Twice-a-day is absorbed in the upper gastrointestinal tract. Absorption is rapid with maximum plasma concentrations occurring after 1 hour in the fasted state and after 2 hours in the fed state.

Half Life

The half-life is 1.9 hours.

Elimination Route

Within 5-6 hours of administration, more than 90% of deferiprone is eliminated from the plasma. 75 to 90% of deferiprone is excreted in the urine as the metabolite.

Pregnancy & Breastfeeding use

Pregnancy Category D. There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective).


Agranulocytosis, pregnancy and lactation.

Storage Condition

Store below 30° C.

Innovators Monograph

You find simplified version here Ferriprox Twice-a-day

Ferriprox Twice-a-day contains Deferiprone see full prescribing information from innovator Ferriprox Twice-a-day Monograph, Ferriprox Twice-a-day MSDS, Ferriprox Twice-a-day FDA label

*** Taking medicines without doctor's advice can cause long-term problems.